US biotechnology company NeOnc Technologies has announced the initiation of a Phase 1/2a clinical trial of NEO100 intranasal perillyl alcohol (POH) for the treatment of glioblastoma multiforme (GBM), an aggressive brain cancer. Five-year survival for patients with GBM is only 3-5%.
The trial is expected to enroll approximately 40 patients in total, and the first patient has already been treated at the Cleveland Clinic, the company said. Patients receive NEO100 four times per day for up to 6 months. According to NeOnc, each treatment takes about 15 minutes, with the drug delivered by a nebulizer with a nose mask.
NeOnc Founder, Chairman and CEO Thomas Chen commented, “We are very excited about initiating our first clinical trial in the US with NEO100. NEO100 is the first GMP quality perillyl alcohol that is FDA approved for human clinical trials. An ongoing clinical trial in Brazil using chemical grade POH has given encouraging results in patients with recurrent GBM, with a number of patients with recurrent GBM achieving extended survival (more than four years) using intranasal POH alone.”
Read the NeOnc Technologies press release.
